

Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab)

Catalog # APR11574

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P01031 & P02768
Reactivity	Human
Clonality	Bispecific
Isotype	VHH-VHH

Additional Information


Target/Specificity	Complement C5,Serum Albumin / SA / HSA
Expression system	CHO

Protein Information

Images






Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 100.00%, determined by SEC-HPLC.

Gefurulimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human- κ + λ -HRP), and read OD450. As shown in fig, Gefurulimab bound to HSA-Fc, and the EC50 was 0.006 nM.



Co-incubation of Gefurulimab with complement protein, then with the addition of Rituximab and Raji cells and incubated for 4 hours. CTG was used to detect the luciferase signal. As shown in fig, Gefurulimab can block rituximab-induced CDC killing, and the IC₅₀ was 18.090 nM.

The detected molecular weight of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 28.99 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.